Topping estimates on Wall Street, Abbott (NYSE:ABT) posted a hefty beat yesterday with its second-quarter financial results. Driving the company’s growth was, in part, its diabetes business unit – sales jumped nearly 40% compared to Q2 in 2017 thanks largely to its sensor-based glucose monitoring system, Freestyle Libre.
“Libre offers a true mass-market opportunity with its unique combination of affordability, accessibility and ease of use and it’s achieving a level of patient adoption that’s unprecedented in the industry with more than 800,000 current users globally,” CEO Miles White said in a call with analysts.
Get the full story at our sister site, Drug Delivery Business News.